The Swedish BioFINDER Study
The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.
News articles
Blood Tests: Not Just for the Impaired?
In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease...
Read more...Looking Good: Immunoassays for Blood Markers
For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical...
Read more...
Recent key publications
- 16 September, 2025
Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers
- 15 September, 2025
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
- 12 August, 2025
Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification
- 25 July, 2025
Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings
X posts
🚨New publication in Brain Communications!
In this study, we show that microglial cells play a key role in Alzheimer's disease, particularly in regulating changes in soluble tau, based on cell-type-specific genetic evidence.
🔗Full paper:
Cell-weighted polygenic risk scores are associated with β-amyloid and tau biomarkers in Alzheimer’s...
Kumar et al. report distinct cellular effects on measures of β-amyloid and tau. Importantly, they also found cell-l...
academic.oup.com
The study was led by Atul Kumar. Thank you to all co-authors: @DivyaBali06, @EStomrud, @SebastianPalmqv, @_JakeVogel_, @OskarHansson9, @NiklasMattsson4, and those not on X.
🚨Paper alert🚨
New publication in @JAMANeuro led by @gesalbla. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer's disease in cognitively unimpaired individuals.
A 🧵...
Plasma P-Tau217 to Identify Preclinical AD
This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in ...
jamanetwork.com
🙏Many thanks to all collaborators in this large study including 12 international cohorts: @DivyaBali06 @A_OrdunaDolado @JosephTherr @EStomrud @NiklasMattsson4 @EmmaCoomans @CharlotteTeuni1 @NesrineR95 @JuandoGispert @vincentDore2 @AzadehFeizpour
@DAlcoleaR @sylv_villeneuve @pedrorosaneto @SuzanneESchind1 @RikOssenkoppele @OskarHansson9 with data from @amsterdamumc @BarcelonaBeta @MayoClinicNeuro @mcgillu @prevent_ad @WashUMedADRC @WisconsinADRC… and those not in X.
🚨New publication in Nature Medicine!
In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting.
Details:
Full paper: https://www.nature.com/articles/s41591-025-03965-4
Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and...
Nature Medicine - A brief, self-administered digital cognitive test, in combination with a blood test, accurately dete...
www.linkedin.com
The study was led by PhD students Pontus Tideman and @karlssonlinda1. Thank you also to all co-authors: @ErikRubenSmith @NiklasMattsson4 @EStomrud @SebastianPalmqv @OskarHansson9 and those not on X.